Biosketch Enriqueta Felip

Enriqueta Felip

efelip@vhio.net

Lloc actual

Cap de grup, Grup de Tumors Toràcics del VHIO
Enriqueta Felip és cap de la Unitat de Càncer Toràcic i de Cap i Coll dins del Departament d’Oncologia de l’Hospital Vall d’Hebron, Barcelona, Espanya.
La professora Felip s’encarrega de la gestió de la neoplàsia toràcica i és responsable dels assaigs de càncer toràcic realitzats pel Departament d’Oncologia. Les línies de recerca actuals són, entre d’altres, l’optimització de la quimioteràpia a les fases inicials de la malaltia, l’avaluació de nous agents i teràpies, la recerca de nous enfocaments farmacogenòmics, la integració d’enfocaments immunoterapèutics en el tractament de pacients amb càncer de pulmó i l’elucidació dels possibles mecanismes de resistència als inhibidors de la tirosina quinasa.

Honors i afiliacions

Premi La Vanguardi de la cipencia La Vanguardia. 2022
Premi a la trajectòria invetsigadora en hospitals de l’ICS. Institut Català de la Salut. 2022
La Dra. Felip és presidenta de la Societat Espanyola d’Oncologia Mèdica (SEOM) per al periode 2021-20123. Va ser vicepresidenta de la SEOM per al període 2019-2021.
La Dra. Felip és actualment membre del Grup Espanyol de Càncer de Pulmó (GECP).
La Dra. Felip també és membre de la Societat Europea d’Oncologia Mèdica (ESMO), la Societat Americana d’Oncologia Clínica (ASCO) i l’Associació Internacional per a l’Estudi del Càncer de Pulmó (IASLC). Actualment és membre del Consell d’Administració de la IASLC (2017-2021). La Dra. Felip va ser copresidenta del 20è Congrés Mundial de Càncer de Pulmó, que va tenir lloc a Barcelona el setembre del 2019. El 2015 va rebre el 1r Premi ESMO Dones per l’Oncologia.
Actualment la Dra. Felip és presidenta de la Comissió d’Oncologia de l’Hospital Universitari Vall d’Hebron i és membre del Comitè Científic Assessor de l’Hospital Parc Taulí de Sabadell.
Ha participat en diverses iniciatives amb organitzacions científiques, per exemple, com a redactora de temes del grup de treball de Guies de Recomanacions Clíniques Mínimes de l’ESMO en matèria de càncer de pulmó i coordinadora de la 1a Conferència de Consens de l’ESMO en càncer de pulmó. Actualment la Dra. Felip és membre del comitè científic del GECP.
També és autora de nombrosos articles revisats per experts i capítols de llibres relacionats amb el camp de les neoplàsies toràciques.

Formació acadèmica

La Dra. Felip es va llicenciar en Medicina per la UAB, on també va fer els seus estudis de doctorat en oncologia mèdica. Va ser professora associada a la Universitat Autònoma de Barcelona (UAB) des del 2010 fins al maig del 2019. Actualment és professora de Medicina a la Universitat de Vic (UVicc-UCC). Participa en la formació d’estudiants de medicina i residents i, sobretot, en la tutoria de becaris.

Àrees de recerca

Ampliar el nostre programa de càncer toràcic translacional en càncer de pulmó no microcític, càncer de pulmó microcític i mesotelioma.
Aplicar les determinacions de la biòpsia líquida.
Contribuir al desenvolupament precoç de fàrmacs, teràpies dirigides i estratègies d’immunoteràpia per al tractament de tumors toràcics i de cap i coll.
Avançar en la medicina de precisió per als pacients amb càncer de pulmó mitjançant la recerca translacional i l’aplicació de tecnologies d’avantguarda i nous enfocaments.
Potenciar les noves teràpies, inclosos els agents immunoterapèutics i dirigits, per al tractament de pacients amb neoplàsies toràciques i de cap i coll.
Aconseguir una comprensió més profunda de l’heterogeneïtat intratumoral i les seves implicacions clíniques.
Continuar reforçant la multidisciplinarietat per a una atenció òptima del pacient.

Premis i reconeixements

Entre els científics d’elit del món dels instituts de recerca acadèmica i les organitzacions comercials -als 21 camps de les categories de ciències i ciències socials- Enriqueta Felip ha estat seleccionada els anys 2019, 2020 i 2021 per la Web of Science’s Highly Cited 2021 Researchers de Clariva’t pels seus excepcionals avenços en la investigació del càncer en la categoria de Medicina Clínica.

Publicacions científiques més rellevants

Felip E, Altorki N, Zhou C, Vallières E, Martínez-Martí A, Rittmeyer A, Chella A, Reck M, Goloborodko O, Huang M, Belleli R, McNally V, Srivastava MK, Bennett E, Gitlitz BJ, Wakelee HA. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial. Ann Oncol. 2023 Oct;34(10):907-919.
Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan-Vidal O, Handzhiev S, Izumi H, Lee JS, Dziadziuszko R, Wolf J, Blackhall F, Reck M, Bustamante Alvarez J, Hummel HD, Dingemans AC, Sands J, Akamatsu H, Owonikoko TK, Ramalingam SS, Borghaei H, Johnson ML, Huang S, Mukherjee S, Minocha M, Jiang T, Martinez P, Anderson ES, Paz-Ares L; DeLLphi-301 Investigators. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. N Engl J Med. 2023 Nov 30;389(22):2063-2075.
Carbonell C, Frigola J, Pardo N, Callejo A, Iranzo P, Valdivia A, Priano I, Cedrés S, Martinez-Marti A, Navarro A, Lenza L, Soleda M, Gonzalo-Ruiz J, Vivancos A, Sansó M, Carcereny E, Morán T, Amat R, Felip E. Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC. Mol Oncol. 2023 May;17(5):779-791.
Solomon BJ, Bauer TM, Mok TSK, Liu G, Mazieres J, de Marinis F, Goto Y, Kim DW, Wu YL, Jassem J, López FL, Soo RA, Shaw AT, Polli A, Messina R, Iadeluca L, Toffalorio F, Felip E. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med. 2023 Apr;11(4):354-366.
Solomon BJ, Bauer TM, Mok TSK, Liu G, Mazieres J, de Marinis F, Goto Y, Kim DW, Wu YL, Jassem J, López FL, Soo RA, Shaw AT, Polli A, Messina R, Iadeluca L, Toffalorio F, Felip E. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med. 2022 Dec 16:S2213-2600(22)00437-4.
Frigola J, Carbonell C, Irazno P, Pardo N, Callejo A, Cedres S, Martinez-Marti A, Navarro A, Soleda M, Jimenez J, Hernandez-Losa J, Vivancos A, Felip E, Amat R. High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC. J Immunother Cancer. 2022 Apr;10(4):e004197.
Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N; CheckMate 816 Investigators. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022 May 26;386(21):1973-1985.
Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA; DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251.
Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, Luft A, Akopov A, Martinez-Marti A, Kenmotsu H, Chen YM, Chella A, Sugawara S, Voong D, Wu F, Yi J, Deng Y, McCleland M, Bennett E, Gitlitz B, Wakelee H; IMpower010 Investigators. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021 Oct 9;398(10308):1344-1357.
Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA; DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan 20;386(3):241-251.
Frigola J, Navarro A, Carbonell C, Callejo A, Iranzo P, Cedrés S, Martinez-Marti A, Pardo N, Saoudi-Gonzalez N, Martinez D, Jimenez J, Sansano I, Mancuso FM, Nuciforo P, Montuenga LM, Sánchez-Cespedes M, Prat A, Vivancos A, Felip E, Amat R. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer. Mol Oncol. 2021 Apr;15(4):887-900.
Felip E, Shaw AT, Bearz A, Camidge DR, Solomon BJ, Bauman JR, Bauer TM, Peters S, Toffalorio F, Abbattista A, Thurm H, Peltz G, Wiltshire R, Besse B. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol. 2021 May;32(5):620-630.
Frigola J, Navarro A, Carbonell C, Callejo A, Iranzo P, Cedrés S, Martinez-Marti A, Pardo N, Saoudi-Gonzalez N, Martinez D, Jimenez J, Sansano I, Mancuso FM, Nuciforo P, MontuengaLM, Sánchez-Cespedes M, Prat A, Vivancos A, Felip E, Amat R. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer. Mol Oncol. 2020 Dec 20. Epub ahead of print
Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC,Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J 2020 Sep 3;383(10):931-943
Felip E, de Braud FG, Maur M, Loong HH, Shaw AT, Vansteenkiste JF, John T, Liu G, Lolkema MP, Selvaggi G, Giannone V, Cazorla P, Baum J, Balbin OA, Wang LV, Lau YY, Scott JW, Tan DS. Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non- Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study. J Thorac Oncol. 2020 Mar;15(3):392-403.
Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Solomon BJ; CROWN Trial Investigators. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. N Engl J Med. 2020 Nov 19;383(21):2018-2029.
Shaw AT, Solomon BJ, Besse B, Bauer TM, Lin CC, Soo RA, Riely GJ, Ou SI, Clancy JS, Li S, Abbattista A, Thurm H, Satouchi M, Camidge DR, Kao S, Chiari R, Gadgeel SM, Felip E, Martini JF. ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2019 Jun 1;37(16):1370-1379.
Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Felip E, Goldman JW, Scalzo C, Jensen E, Kush DA, Hui R. Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol. 2019 Oct 1;37(28):2518-2527.
Subbiah V, Gervais R, Riely G, Hollebecque A, Blay JY, Felip E, Schuler M, Gonçalves A, Italiano A, Keedy V, Chau I, Puzanov I, Raje NS, Meric-Bernstam F, Makrutzki M, Riehl T, Pitcher B, Baselga J, Hyman DM. Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. JCO Precis Oncol. 2019 Jun 27;3:PO.18.00266.
Dziadziuszko R, Smit EF, Dafni U, Wolf J, Wasąg B, Biernat W, Finn SP, Kammler R, Tsourti Z, Rabaglio M, Ruepp B, Roschitzki-Voser H, Stahel RA, Felip E, Peters SJ. Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). Thorac Oncol. 2019 Jun;14(6):1086-1094.
Solomon BJ, Cappuzzo F, Felip E, Blackhall FH, Costa DB, Kim DW, Nakagawa K, Wu YL, Mekhail T, Paolini J, Tursi J, Usari T, Wilner KD, Selaru P, Mok TS. Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. J Clin Onco. 2016 Aug 20;34(24):2858-65.
Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, Pietanza MC, Wu YL, Zielinski C, Thomas M, Felip E, Gold K, Horn L, Aerts J, Nakagawa K, Lorigan P, Pieters A, Kong Sanchez T, Fairchild J, Spigel D. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. J Clin Oncol. 2016 Jul 25. pie: JCO676601. [Epub ahead of print]
Cedrés S, Ponce-Aix S, Pardo-Aranda N, Navarro-Mendivil A, Martinez-Marti A, Zugazagoitia J, Sansano I, Montoro MA, Enguita A, Felip E. Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). Lung Cancer. 2016 Jun;96:1-6.
Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016 Apr 9;387(10027):1540-50.
Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016 Apr; 387(10027): 1540-50
Eberhardt WE, De Ruysscher D, Weder W, Le Péchoux C, De Leyn P, Hoffmann H, Westeel V, Stahel R, Felip E, Peters S. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann. Oncol. 2015 Aug; 26(8): 1573-88
Heigener DF, Pereira JR, Felip E, Mazal J, Manzyuk L, Tan EH, Merimsky O, Sarholz B, Esser R, Gatzemeier U. Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial. Target Oncol 2015 Jun; 10(2): 255-65
Felip E, Concha A, de Castro J, Gómez-Román J, Garrido P, Ramírez J, Isla D, Sanz J, Paz-Ares L, López-Ríos F. Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol 2015 Feb; 17(2): 103-12
Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, Ercan D, Matthews SE, Cantarini M, Barrett JC, Janne PA, Oxnard GR. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.Nat. Med. 2015 Jun; 21(6): 560-2
De Mattos-Arruda L, Mayor R, Ng CK, Weigelt B, Martínez-Ricarte F, Torrejón D, Oliveira M, Arias A, Raventós C, Tang J, Guerini-Rocco E, Martínez-Sáez E, Lois S, Marín O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramón y Cajal S, Carles J, Rodón J, González-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 2015; 6: 8839
Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Pálmer HG, Dawood S, Rodón J, Cajal SR, Campo JM, Felip E, Tabernero J, Cortes J. ERRATUM: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity. Sci Rep 2015; 5: 8179
Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 2015 Apr; 372(18): 1689-99
Karachaliou N, Codony-Servat J, Teixidó C, Pilotto S, Drozdowskyj A, Codony-Servat C, Giménez-Capitán A, Molina-Vila MA, Bertran-Alamillo J, Gervais R, Massuti B, Morán T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S, González-Cao M, Morales-Espinosa D, Verlicchi A, Crisetti E, Chaib I, Santarpia M, Luis Ramírez J, Bosch-Barrera J, Felipe Cardona A, de Marinis F, Lopez-Vivanco G, Miguel Sánchez J, Vergnenegre A, Sánchez Hernández JJ, Sperduti I, Bria E, Rosell R. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. Sci Rep 2015; 5: 17499

Totes les publicacions

Yang JC, Zhou C, Jänne PA, Ramalingam SS, Kim TM, Riely GJ, Spira AI, Piotrowska Z, Mekhail T, Garcia Campelo MR, Felip E, Bazhenova L, Jin S, Kaur M, Diderichsen PM, Gupta N, Bunn V, Lin J, N Churchill E, Mehta M, Nguyen D. Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer. Expert Rev Anticancer Ther. 2023 Jan;23(1):95-106. Epub 2022 Dec 28.
Barlesi F, Isambert N, Felip E, Cho BC, Lee DH, Peguero J, Jerusalem G, Penel N, Saada-Bouzid E, Garrido P, Helwig C, Locke G, Ojalvo LS, Gulley JL. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors. Oncologist. 2022 Dec 26:oyac253. doi: 10.1093/oncolo/oyac253. Epub ahead of print.
Isla D, Lozano MD, Paz-Ares L, Salas C, de Castro J, Conde E, Felip E, Gómez-Román J, Garrido P, Enguita AB. New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2022 Dec 26. doi: 10.1007/s12094-022-03046-9. Epub ahead of print.
Ahn MJ, Kim HR, Yang JCH, Han JY, Li JY, Hochmair MJ, Chang GC, Delmonte A, Lee KH, Campelo RG, Gridelli C, Spira AI, Califano R, Griesinger F, Ghosh S, Felip E, Kim DW, Liu Y, Zhang P, Popat S, Camidge DR. Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study. Clin Lung Cancer. 2022 Dec;23(8):720-730.
Prat A, Paz-Ares L, Juan M, Felip E, Garralda E, González B, Arance A, Martín-Liberal J, Gavilá J, López-González A, Cejalvo JM, Izarzugaza Y, Amillano K, Corbacho JG, Saura C, Racca F, Hierro C, Sanfeliu E, Gonzalez X, Canes J, Villacampa G, Salvador F, Pascual T, Mesía R, Cervantes A, Tabernero J. SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA. Future Oncol. 2022 Oct 6. Epub ahead of print.
Lazar V, Girard N, Raymond E, Martini JF, Galbraith S, Raynaud J, Bresson C, Solomon B, Magidi S, Nechushtan H, Onn A, Berger R, Chen H, Al-Omari A, Ikeda S, Lassen U, Sekacheva M, Felip E, Tabernero J, Batist G, Spatz A, Pramesh CS, Girard P, Blay JY, Philip T, Berindan-Neagoe I, Porgador A, Rubin E, Kurzrock R, Schilsky RL. Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies. JCO Precis Oncol. 2022 Sep;6:e2200072.
Ou SI, Nishio M, Ahn MJ, Mok T, Barlesi F, Zhou C, Felip E, de Marinis F, Kim SW, Pérol M, Liu G, Migliorino MR, Kim DW, Novello S, Bearz A, Garrido P, Mazieres J, Morabito A, Lin HM, Yang H, Niu H, Zhang P, Kim ES. Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2). J Thorac Oncol. 2022 Dec;17(12):1404-1414.
Sabaté Gallego M, Pérez Esquirol E, Garcia Doladé N, Vidal Guitart X, Carreras Soler MJ, Farriols Danés A, Felip E, Braña I, Carles Galceran J, Morales Barrera R, Muñoz-Couselo E, Agustí Escasany A. Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1/PD-L1 inhibitors in real-world practice. Front Med (Lausanne). 2022 Aug 22;9:891179.
Ahn MJ, Kim HR, Yang JCH, Han JY, Li JY, Hochmair MJ, Chang GC, Delmonte A, Lee KH, Campelo RG, Gridelli C, Spira AI, Califano R, Griesinger F, Ghosh S, Felip E, Kim DW, Liu Y, Zhang P, Popat S, Camidge DR. Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study. Clin Lung Cancer. 2022 Dec;23(8):720-730.
Felip E, Smit EF, Molina-Vila MA, Dafni U, Massuti B, Berghmans T, de Marinis F, Passiglia F, Dingemans AC, Cobo M, Viteri S, Britschgi C, Cuffe S, Provencio M, Merkelbach-Bruse S, Andriakopoulou C, Kammler R, Ruepp B, Roschitzki-Voser H, Peters S, Wolf J, Stahel R; ETOP 12-17 ALERT-lung Collaborators. Alectinib for the treatment of pretreated RET-rearranged advanced NSCLC: Results of the ETOP ALERT-lung trial. Lung Cancer. 2022 Oct;172:94-99.
Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel SM, Cheema P, Cobo M, Andric Z, Barrios CH, Yamaguchi M, Dansin E, Danchaivijitr P, Johnson M, Novello S, Mathisen MS, Shagan SM, Schleifman E, Wang J, Yan M, Mocci S, Voong D, Fabrizio DA, Shames DS, Riehl T, Gandara DR, Mok T. Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial. Nat Med. 2022 Sep;28(9):1831-1839.
Vaz-Luis I, Masiero M, Cavaletti G, Cervantes A, Chlebowski RT, Curigliano G, Felip E, Ferreira AR, Ganz PA, Hegarty J, Jeon J, Johansen C, Joly F, Jordan K, Koczwara B, Lagergren P, Lambertini M, Lenihan D, Linardou H, Loprinzi C, Partridge AH, Rauh S, Steindorf K, van der Graaf W, van de Poll-Franse L, Pentheroudakis G, Peters S, Pravettoni G. ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe. Ann Oncol. 2022 Nov;33(11):1119-1133.
Wermke M, Felip E, Gambardella V, Kuboki Y, Morgensztern D, Hamed ZO, Liu M, Studeny M, Owonikoko TK. Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas. Future Oncol. 2022 Aug;18(24):2639-2649.
Tan DSW, Kim SW, Ponce Aix S, Sequist LV, Smit EF, Yang JCH, Hida T, Toyozawa R, Felip E, Wolf J, Grohé C, Leighl NB, Riely G, Cui X, Zou M, Ghebremariam S, O’Sullivan-Djentuh L, Belli R, Giovannini M, Kim DW. Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study. Eur J Cancer. 2022 Sep;172:276-286.
Iranzo P, Callejo A, Assaf JD, Molina G, Lopez DE, Garcia-Illescas D, Pardo N, Navarro A, Martinez-Marti A, Cedres S, Carbonell C, Frigola J, Amat R, Felip E. Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer. Front Med (Lausanne). 2022 May 30;9:875974.
Morfouace M, Novello S, Stevovic A, Dooms C, Janžič U, Berghmans T, Dziadziuszko R, Gorlia T, Felip E, Paz-Ares L, Mazieres J, O’Brien M, Bironzo P, Vansteenkiste J, Lacroix L, Dingemans AC, Golfinopoulos V, Besse B. Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform. Sci Rep. 2022 May 18;12(1):8342. doi: 10.1038/s41598-022-12056-0. PMID: 35585228; PMCID: PMC9117328.
Frigola J, Carbonell C, Irazno P, Pardo N, Callejo A, Cedres S, Martinez-Marti A, Navarro A, Soleda M, Jimenez J, Hernandez-Losa J, Vivancos A, Felip E, Amat R. High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC. J Immunother Cancer. 2022 Apr;10(4):e004197.
Veillon R, Sakai H, Le X, Felip E, Cortot AB, Smit EF, Park K, Griesinger F, Britschgi C, Wu YL, Melosky B, Baijal S, Jr GC, Sedova M, Berghoff K, Otto G, Paik PK. Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management. Clin Lung Cancer. 2022 Jun;23(4):320-332.
Mirallas O, Bosch-Schips M, Pardo N, Aubanell A, Salcedo-Allende MT, Callejo A, Iranzo P, Tabernero J, Felip E. Hepatic Rupture as the Initial Presentation of an EGFR-Mutated Lung Adenocarcinoma: A Case Report. Front Oncol. 2022 Mar 30;12:837630.
Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N; CheckMate 816 Investigators. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022 May 26;386(21):1973-1985.
Solomon B, Callejo A, Bar J, Berchem G, Bazhenova L, Saintigny P, Wunder F, Raynaud J, Girard N, Lee JJ, Sulaiman R, Prouse B, Bresson C, Ventura H, Magidi S, Rubin E, Young B, Onn A, Leyland-Jones B, Schilsky RL, Lazar V, Felip E, Kurzrock R. A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. Cancer Med. 2022 Jul;11(14):2790-2800.
Cedres S, Felip E. 3-Year CheckMate743 outcomes: ringing in immunotherapy for the treatment of malignant pleural mesothelioma. Ann Oncol. 2022 May;33(5):457-459.
Santoro A, Su WC, Navarro A, Simonelli M, Ch Yang J, Ardizzoni A, Barlesi F, Hyoung Kang J, DiDominick S, Abdelhady A, Chen X, Stammberger U, Felip E. Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer. Lung Cancer. 2022 Apr;166:170-177.
Felip E, Moreno V, Morgensztern D, Curigliano G, Rutkowski P, Trigo JM, Calvo A, Kowalski D, Cortinovis D, Plummer R, Maio M, Ascierto PA, Vladimirov VI, Cervantes A, Zudaire E, Hazra A, T’jollyn H, Bandyopadhyay N, Greger JG, Attiyeh E, Xie H, Calvo E. First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. Cancer Chemother Pharmacol. 2022 Apr;89(4):499-514.
Levy B, Barlesi F, Paz-Ares L, Bennouna J, Erman M, Felip E, Isla D, Ryun Kim H, Kim SW, Madelaine J, Molinier O, Özgüroğlu M, Rodríguez Abreu D, Adeniji A, Lorence RM, Voccia I, Chisamore MJ, Riess JW. Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO). Lung Cancer. 2022 Apr;166:107-113.
Pérol M, Felip E, Dafni U, Polito L, Pal N, Tsourti Z, Ton TGN, Merritt D, Morris S, Stahel R, Peters S. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data. Ann Oncol. 2022 May;33(5):511-521.
Remon J, Bernabé R, Diz P, Felip E, González-Larriba JL, Lázaro M, Mielgo-Rubio X, Sánchez A, Sullivan I, Massutti B. SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021). Clin Transl Oncol. 2022 Apr;24(4):635-645.
Passaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn MJ, Arcila ME, Arrieta O, Planchard D, de Marinis F, Dingemans AM, Dziadziuszko R, Faivre-Finn C, Feldman J, Felip E, Curigliano G, Herbst R, Jänne PA, John T, Mitsudomi T, Mok T, Normanno N, Paz-Ares L, Ramalingam S, Sequist L, Vansteenkiste J, Wistuba II, Wolf J, Wu YL, Yang SR, Yang JCH, Yatabe Y, Pentheroudakis G, Peters S. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann Oncol. 2022 May;33(5):466-487.
Burtness B, Rischin D, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Ge J, Swaby RF, Gumuscu B, Harrington K. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. J Clin Oncol. 2022 Jul 20;40(21):2321-2332.
Lorini L, Perri F, Vecchio S, Belgioia L, Vinches M, Brana I, Elad S, Bossi P. Confounding factors in the assessment of oral mucositis in head and neck cancer. Support Care Cancer. 2022 Oct;30(10):8455-8463.
Rischin D, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Braña I, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Ishak WZW, Hong RL, Mendoza RG, Jia L, Chirovsky D, Norquist J, Jin F, Burtness B. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. Oral Oncol. 2022 May;128:105815.
Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, Luft A, Akopov A, Martinez-Marti A, Kenmotsu H, Chen YM, Chella A, Sugawara S, Voong D, Wu F, Yi J, Deng Y, McCleland M, Bennett E, Gitlitz B, Wakelee H; IMpower010 Investigators. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021 Oct 9;398(10308):1344-1357. doi: 10.1016/S0140-6736(21)02098-5. Epub 2021 Sep 20. Erratum in: Lancet. 2021 Sep 23;: PMID: 34555333.
Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, Pluzanski A, Arrieta O, Frontera OA, Chiari R, Butts C, Wójcik-Tomaszewska J, Coudert B, Garassino MC, Ready N, Felip E, García MA, Waterhouse D, Domine M, Barlesi F, Antonia S, Wohlleber M, Gerber DE, Czyzewicz G, Spigel DR, Crino L, Eberhardt WEE, Li A, Marimuthu S, Brahmer J. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. J Clin Oncol. 2021 Mar 1;39(7):723-733. doi: 10.1200/JCO.20.01605. Epub 2021 Jan 15. Erratum in: J Clin Oncol. 2021 Apr 1;39(10):1190. PMID: 33449799; PMCID: PMC8078445.
Owonikoko TK, Park K, Govindan R, Ready N, Reck M, Peters S, Dakhil SR, Navarro A, Rodríguez-Cid J, Schenker M, Lee JS, Gutierrez V, Percent I, Morgensztern D, Barrios CH, Greillier L, Baka S, Patel M, Lin WH, Selvaggi G, Baudelet C, Baden J, Pandya D, Doshi P, Kim HR. Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. J Clin Oncol. 2021 Apr 20;39(12):1349-1359. doi: 10.1200/JCO.20.02212. Epub 2021 Mar 8. PMID: 33683919; PMCID: PMC8078251.
Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Salman P, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, John T, Carbone DP, Meadows-Shropshire S, Agrawal S, Oukessou A, Yan J, Reck M. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Feb;22(2):198-211. doi: 10.1016/S1470-2045(20)30641-0. Epub 2021 Jan 18. Erratum in: Lancet Oncol. 2021 Mar;22(3):e92. PMID: 33476593.
Pinato DJ, Tabernero J, Bower M, Scotti L, Patel M, Colomba E, Dolly S, Loizidou A, Chester J, Mukherjee U, Zambelli A, Dalla Pria A, Aguilar-Company J, Ottaviani D, Chowdhury A, Merry E, Salazar R, Bertuzzi A, Brunet J, Lambertini M, Tagliamento M, Pous A, Sita-Lumsden A, Srikandarajah K, Colomba J, Pommeret F, Seguí E, Generali D, Grisanti S, Pedrazzoli P, Rizzo G, Libertini M, Moss C, Evans JS, Russell B, Harbeck N, Vincenzi B, Biello F, Bertulli R, Liñan R, Rossi S, Carmona-García MC, Tondini C, Fox L, Baggi A, Fotia V, Parisi A, Porzio G, Saponara M, Cruz CA, García-Illescas D, Felip E, Roqué Lloveras A, Sharkey R, Roldán E, Reyes R, Earnshaw I, Ferrante D, Marco-Hernández J, Ruiz-Camps I, Gaidano G, Patriarca A, Bruna R, Sureda A, Martinez-Vila C, Sanchez de Torre A, Cantini L, Filetti M, Rimassa L, Chiudinelli L, Franchi M, Krengli M, Santoro A, Prat A, Van Hemelrijck M, Diamantis N, Newsom-Davis T, Gennari A, Cortellini A; OnCovid study group. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. Lancet Oncol. 2021 Dec;22(12):1669-1680. doi: 10.1016/S1470-2045(21)00573-8. Epub 2021 Nov 3. PMID: 34741822; PMCID: PMC8565932.
Schoenfeld AJ, Antonia SJ, Awad MM, Felip E, Gainor J, Gettinger SN, Hodi FS, Johnson ML, Leighl NB, Lovly CM, Mok T, Perol M, Reck M, Solomon B, Soria JC, Tan DSW, Peters S, Hellmann MD. Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer. Ann Oncol. 2021 Dec;32(12):1597-1607. doi: 10.1016/j.annonc.2021.08.2151. Epub 2021 Sep 3. PMID: 34487855.
Felip E, Shaw AT, Bearz A, Camidge DR, Solomon BJ, Bauman JR, Bauer TM, Peters S, Toffalorio F, Abbattista A, Thurm H, Peltz G, Wiltshire R, Besse B. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol. 2021 May;32(5):620-630. doi: 10.1016/j.annonc.2021.02.012. Epub 2021 Feb 24. PMID: 33639216.
Rodríguez-Abreu D, Powell SF, Hochmair MJ, Gadgeel S, Esteban E, Felip E, Speranza G, De Angelis F, Dómine M, Cheng SY, Bischoff HG, Peled N, Reck M, Hui R, Garon EB, Boyer M, Kurata T, Yang J, Pietanza MC, Souza F, Garassino MC. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021 Jul;32(7):881-895. doi: 10.1016/j.annonc.2021.04.008. Epub 2021 Apr 22. PMID: 33894335.
Spigel DR, Vicente D, Ciuleanu TE, Gettinger S, Peters S, Horn L, Audigier-Valette C, Pardo Aranda N, Juan-Vidal O, Cheng Y, Zhang H, Shi M, Luft A, Wolf J, Antonia S, Nakagawa K, Fairchild J, Baudelet C, Pandya D, Doshi P, Chang H, Reck M. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331^☆. Ann Oncol. 2021 May;32(5):631-641. doi: 10.1016/j.annonc.2021.01.071. Epub 2021 Feb 1. PMID: 33539946.
Pérol M, Felip E, Dafni U, Polito L, Pal N, Tsourti Z, Ton TGN, Merritt D, Morris S, Stahel R, Peters S. Effectiveness of PD-(L)1 Inhibitors Alone or in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Non-Squamous Non-Small Cell Lung Cancer (nsq-NSCLC) With PD-L1-High Expression Using Real-World Data. Ann Oncol. 2022 Feb 23:S0923-7534(22)00124-7. doi: 10.1016/j.annonc.2022.02.008. Epub ahead of print. PMID: 35218887.
Zhou C, Ramalingam SS, Kim TM, Kim SW, Yang JC, Riely GJ, Mekhail T, Nguyen D, Garcia Campelo MR, Felip E, Vincent S, Jin S, Griffin C, Bunn V, Lin J, Lin HM, Mehta M, Jänne PA. Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial. JAMA Oncol. 2021 Dec 1;7(12):e214761. doi: 10.1001/jamaoncol.2021.4761. Epub 2021 Dec 16. Erratum in: JAMA Oncol. 2022 Feb 24;: PMID: 34647988; PMCID: PMC8517885.
Jabbour SK, Lee KH, Frost N, Breder V, Kowalski DM, Pollock T, Levchenko E, Reguart N, Martinez-Marti A, Houghton B, Paoli JB, Safina S, Park K, Komiya T, Sanford A, Boolell V, Liu H, Samkari A, Keller SM, Reck M. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial. JAMA Oncol. 2021 Jun 4;7(9):1–9. doi: 10.1001/jamaoncol.2021.2301. Epub ahead of print. PMID: 34086039; PMCID: PMC8446818.
Loo Yau H, Bell E, Ettayebi I, de Almeida FC, Boukhaled GM, Shen SY, Allard D, Morancho B, Marhon SA, Ishak CA, Gonzaga IM, da Silva Medina T, Singhania R, Chakravarthy A, Chen R, Mehdipour P, Pommey S, Klein C, Amarante-Mendes GP, Roulois D, Arribas J, Stagg J, Brooks DG, De Carvalho DD. DNA hypomethylating agents increase activation and cytolytic activity of CD8⁺ T cells. Mol Cell. 2021 Apr 1;81(7):1469-1483.e8. doi: 10.1016/j.molcel.2021.01.038. Epub 2021 Feb 19. PMID: 33609448.
Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, Garcia Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira AI, Gettinger SN, Tiseo M, Lin HM, Liu Y, Vranceanu F, Niu H, Zhang P, Popat S. Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. J Thorac Oncol. 2021 Dec;16(12):2091-2108. doi: 10.1016/j.jtho.2021.07.035. Epub 2021 Sep 16. PMID: 34537440.
Peters S, Felip E, Dafni U, Tufman A, Guckenberger M, Álvarez R, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Lambrecht M, Andratschke N, Tsourti Z, Piguet AC, Roschitzki-Voser H, Gasca-Ruchti A, Vansteenkiste J, Stahel RA, De Ruysscher D. Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14). J Thorac Oncol. 2021 Feb;16(2):278-288. doi: 10.1016/j.jtho.2020.10.129. Epub 2020 Nov 12. Erratum in: J Thorac Oncol. 2021 May 26;: PMID: 33188912.
Jassem J, de Marinis F, Giaccone G, Vergnenegre A, Barrios CH, Morise M, Felip E, Oprean C, Kim YC, Andric Z, Mocci S, Enquist I, Komatsubara K, McCleland M, Kuriki H, Villalobos M, Phan S, Spigel DR, Herbst RS. Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC. J Thorac Oncol. 2021 Nov;16(11):1872-1882. doi: 10.1016/j.jtho.2021.06.019. Epub 2021 Jul 12. PMID: 34265434.
Sierra-Rodero B, Cruz-Bermúdez A, Nadal E, Garitaonaindía Y, Insa A, Mosquera J, Casal-Rubio J, Dómine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Massuti B, Laza-Briviesca R, Casarrubios M, García-Grande A, Romero A, Franco F, Provencio M. Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. J Immunother Cancer. 2021 Aug;9(8):e002804. doi: 10.1136/jitc-2021-002804. PMID: 34446577; PMCID: PMC8395363.
Dettorre GM, Dolly S, Loizidou A, Chester J, Jackson A, Mukherjee U, Zambelli A, Aguilar-Company J, Bower M, Sng CCT, Salazar R, Bertuzzi A, Brunet J, Mesia R, Sita-Lumsden A, Seguí E, Biello F, Generali D, Grisanti S, Seeva P, Rizzo G, Libertini M, Maconi A, Moss C, Russell B, Harbeck N, Vincenzi B, Bertulli R, Ottaviani D, Liñan R, Marrari A, Carmona-García MC, Chopra N, Tondini CA, Mirallas O, Tovazzi V, Fotia V, Cruz CA, Saoudi-Gonzalez N, Felip E, Roqué A, Lee AJX, Newsom-Davis T, García-Illescas D, Reyes R, Wong YNS, Ferrante D, Scotti L, Marco-Hernández J, Ruiz-Camps I, Patriarca A, Rimassa L, Chiudinelli L, Franchi M, Santoro A, Prat A, Gennari A, Van Hemelrijck M, Tabernero J, Diamantis N, Pinato DJ; OnCovid study group. Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. J Immunother Cancer. 2021 Mar;9(3):e002277. doi: 10.1136/jitc-2020-002277. Erratum in: J Immunother Cancer. 2021 Jun;9(6): PMID: 33753569; PMCID: PMC7985977.
Casarrubios M, Cruz-Bermúdez A, Nadal E, Insa A, García Campelo MDR, Lázaro M, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, de Castro-Carpeño J, Cobo M, López-Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Massuti B, Barquín M, Laza-Briviesca R, Sierra-Rodero B, Parra ER, Sanchez-Espiridion B, Rocha P, Kadara H, Wistuba II, Romero A, Calvo V, Provencio M. Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy. Clin Cancer Res. 2021 Nov 1;27(21):5878-5890. doi: 10.1158/1078-0432.CCR-21-1200. Epub 2021 Aug 10. PMID: 34376534.
Laza-Briviesca R, Cruz-Bermúdez A, Nadal E, Insa A, García-Campelo MDR, Huidobro G, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Massuti B, Casarrubios M, Sierra-Rodero B, Tarín C, García-Grande A, Haymaker C, Wistuba II, Romero A, Franco F, Provencio M. Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. Clin Transl Med. 2021 Jul;11(7):e491. doi: 10.1002/ctm2.491. PMID: 34323406; PMCID: PMC8288017.
Ligero M, Garcia-Ruiz A, Viaplana C, Villacampa G, Raciti MV, Landa J, Matos I, Martin-Liberal J, Ochoa-de-Olza M, Hierro C, Mateo J, Gonzalez M, Morales-Barrera R, Suarez C, Rodon J, Elez E, Braña I, Muñoz-Couselo E, Oaknin A, Fasani R, Nuciforo P, Gil D, Rubio-Perez C, Seoane J, Felip E, Escobar M, Tabernero J, Carles J, Dienstmann R, Garralda E, Perez-Lopez R. A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Radiology. 2021 Apr;299(1):109-119. doi: 10.1148/radiol.2021200928. Epub 2021 Jan 26. PMID: 33497314.
Pinato DJ, Scotti L, Gennari A, Colomba-Blameble E, Dolly S, Loizidou A, Chester J, Mukherjee U, Zambelli A, Aguilar-Company J, Bower M, Galazi M, Salazar R, Bertuzzi A, Brunet J, Mesia R, Sita-Lumsden A, Colomba J, Pommeret F, Seguí E, Biello F, Generali D, Grisanti S, Rizzo G, Libertini M, Moss C, Evans JS, Russell B, Wuerstlein R, Vincenzi B, Bertulli R, Ottaviani D, Liñan R, Marrari A, Carmona-García MC, Sng CCT, Tondini C, Mirallas O, Tovazzi V, Fotia V, Cruz CA, Saoudi-Gonzalez N, Felip E, R Lloveras A, Lee AJX, Newsom-Davis T, Sharkey R, Chung C, García-Illescas D, Reyes R, Sophia Wong YN, Ferrante D, Marco-Hernández J, Ruiz-Camps I, Gaidano G, Patriarca A, Sureda A, Martinez-Vila C, Sanchez de Torre A, Rimassa L, Chiudinelli L, Franchi M, Krengli M, Santoro A, Prat A, Tabernero J, V Hemelrijck M, Diamantis N, Cortellini A; OnCovid study group. Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. Eur J Cancer. 2021 Jun;150:190-202. doi: 10.1016/j.ejca.2021.03.035. Epub 2021 Apr 6. PMID: 33932726; PMCID: PMC8023206.
Matos I, Villacampa G, Hierro C, Martin-Liberal J, Berché R, Pedrola A, Braña I, Azaro A, Vieito M, Saavedra O, Gardeazabal I, Hernando-Calvo A, Alonso G, Galvao V, Ochoa de Olza M, Ros J, Viaplana C, Muñoz-Couselo E, Elez E, Rodon J, Saura C, Macarulla T, Oaknin A, Carles J, Felip E, Tabernero J, Dienstmann R, Garralda E. Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials. Eur J Cancer. 2021 Sep;155:168-178. doi: 10.1016/j.ejca.2021.05.040. Epub 2021 Aug 9. PMID: 34385069.
Lazar V, Magidi S, Girard N, Savignoni A, Martini JF, Massimini G, Bresson C, Berger R, Onn A, Raynaud J, Wunder F, Berindan-Neagoe I, Sekacheva M, Braña I, Tabernero J, Felip E, Porgador A, Kleinman C, Batist G, Solomon B, Tsimberidou AM, Soria JC, Rubin E, Kurzrock R, Schilsky RL. Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. NPJ Precis Oncol. 2021 Apr 28;5(1):33. doi: 10.1038/s41698-021-00171-6. PMID: 33911192; PMCID: PMC8080819.
Garrigós L, Saura C, Martinez-Vila C, Zambelli A, Bower M, Pistilli B, Lambertini M, Ottaviani D, Diamantis N, Lumsden A, Pernas S, Generali D, Seguí E, Viñas G, Felip E, Sanchez A, Rizzo G, Santoro A, Cortellini A, Perone Y, Chester J, Iglesias M, Betti M, Vincenzi B, Libertini M, Mazzoni F, Zoratto F, Berardi R, Guida A, Wuerstlein R, Loizidou A, Sharkey R, Aguilar Company J, Matas M, Saggia C, Chiudinelli L, Colomba-Blameble E, Galazi M, Mukherjee U, Van Hemelrijck M, Marin M, Strina C, Prat A, Pla H, Ciruelos EM, Bertuzzi A, Del Mastro L, Porzio G, Newsom-Davis T, Ruiz I, Delany MB, Krengli M, Fotia V, Viansone A, Chopra N, Romeo M, Salazar R, Perez I, d’Avanzo F, Franchi M, Milani M, Pommeret F, Tucci M, Pedrazzoli P, Harbeck N, Ferrante D, Pinato DJ, Gennari A. COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. Ther Adv Med Oncol. 2021 Nov 2;13:17588359211053416. doi: 10.1177/17588359211053416. PMID: 34777582; PMCID: PMC8573484.
Soosaipillai G, Wu A, Dettorre GM, Diamantis N, Chester J, Moss C, Aguilar-Company J, Bower M, Sng CC, Salazar R, Brunet J, Jones E, Mesia R, Jackson A, Mukherjee U, Sita-Lumsden A, Seguí E, Ottaviani D, Carbó A, Benafif S, Würstlein R, Carmona C, Chopra N, Cruz CA, Swallow J, Saoudi N, Felip E, Galazi M, Garcia-Fructuoso I, Lee AJX, Newsom-Davis T, Wong YNS, Sureda A, Maluquer C, Ruiz-Camps I, Cabirta A, Prat A, Loizidou A, Gennari A, Ferrante D, Tabernero J, Russell B, Van Hemelrijck M, Dolly S, Hulbert-Williams NJ, Pinato DJ. Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. Ther Adv Med Oncol. 2021 Sep 2;13:17588359211042224. doi: 10.1177/17588359211042224. PMID: 34497669; PMCID: PMC8419540.
Martinez-Marti A, Felip E, Mancuso FM, Caratú G, Matito J, Nuciforo P, Sansano I, Diaz-Mejia N, Cedrés S, Callejo A, Iranzo P, Pardo N, Miquel JM, Navarro A, Vivancos A, Sansó M. Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer. Br J Cancer. 2021 Nov;125(11):1561-1569. doi: 10.1038/s41416-021-01558-9. Epub 2021 Oct 1. PMID: 34599295; PMCID: PMC8608949.
Alvarez-Manceñido F, Jimenez-Fonseca P, Carmona-Bayonas A, Arrazubi V, Hernandez R, Cano JM, Custodio A, Pericay Pijaume C, Aguado G, Martínez Lago N, Sánchez Cánovas M, Cacho Lavin D, Visa L, Martinez-Torron A, Arias-Martinez A, López F, Limón ML, Vidal Tocino R, Fernández Montes A, Alsina M, Pimentel P, Reguera P, Martín Carnicero A, Ramchandani A, Granja M, Azkarate A, Martín Richard M, Serra O, Hernández Pérez C, Hurtado A, Gil-Negrete A, Sauri T, Morales Del Burgo P, Gallego J. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry. Gastric Cancer. 2021 Jul;24(4):926-936. doi: 10.1007/s10120-021-01169-6. Epub 2021 Mar 2. PMID: 33651195.
Park K, Jӓnne PA, Kim DW, Han JY, Wu MF, Lee JS, Kang JH, Lee DH, Cho BC, Yu CJ, Pang YK, Felip E, Kim H, Baek E, Noh YS. Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study. Cancer. 2021 May 1;127(9):1407-1416. doi: 10.1002/cncr.33385. Epub 2021 Jan 12. PMID: 33434335; PMCID: PMC8247868.
Callejo A, Frigola J, Iranzo P, Carbonell C, Diaz N, Marmolejo D, Assaf JD, Cedrés S, Martinez-Marti A, Navarro A, Pardo N, Amat R, Felip E. Interrelations between Patients’ Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients. Cancers (Basel). 2021 Jun 29;13(13):3249. doi: 10.3390/cancers13133249. PMID: 34209601; PMCID: PMC8268100.
Frigola J, Navarro A, Carbonell C, Callejo A, Iranzo P, Cedrés S, Martinez-Marti A, Pardo N, Saoudi-Gonzalez N, Martinez D, Jimenez J, Sansano I, Mancuso FM, Nuciforo P, Montuenga LM, Sánchez-Cespedes M, Prat A, Vivancos A, Felip E, Amat R. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer. Mol Oncol. 2021 Apr;15(4):887-900. doi: 10.1002/1878-0261.12891. Epub 2021 Jan 6. PMID: 33342055; PMCID: PMC8024716.
Berghoff AS, Sessa C, Yang JC, Tsourti Z, Tsang J, Tabernero J, Peters S, Linardou H, Letsch A, Haanen J, Garralda E, Garassino MC, Furness AJS, Felip E, Dimopoulou G, Dafni U, Choo SP, Banerjee S, Bajpai J, Adjei AA, Garrido P. Female leadership in oncology-has progress stalled? Data from the ESMO W4O authorship and monitoring studies. ESMO Open. 2021 Dec;6(6):100281. doi: 10.1016/j.esmoop.2021.100281. Epub 2021 Oct 19. PMID: 34924143; PMCID: PMC8710465.
Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Reyes F, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, Paz-Ares L, Carbone DP, Memaj A, Marimuthu S, Zhang X, Tran P, John T. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. ESMO Open. 2021 Oct;6(5):100273. doi: 10.1016/j.esmoop.2021.100273. Epub 2021 Oct 1. Erratum in: ESMO Open. 2021 Dec;6(6):100345. PMID: 34607285; PMCID: PMC8493593.
Elez E, Ayala F, Felip E, García Campelo R, García Carbonero R, García Donás J, González Del Alba A, González Flores E, Hidalgo J, Isla D, Majem M, Rodríguez Lescure Á, Safont MJ, Santaballa A, Villacampa G, Vera R, Garrido P. Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM). ESMO Open. 2021 Apr;6(2):100048. doi: 10.1016/j.esmoop.2021.100048. Epub 2021 Feb 6. PMID: 33556897; PMCID: PMC7872979.
Garrido P, Adjei AA, Bajpai J, Banerjee S, Berghoff AS, Choo SP, Felip E, Furness AJS, Garralda E, Haanen J, Letsch A, Linardou H, Peters S, Sessa C, Tabernero J, Tsang J, Yang JC, Garassino MC. Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey. ESMO Open. 2021 Jun;6(3):100131. doi: 10.1016/j.esmoop.2021.100131. Epub 2021 May 25. PMID: 34144778; PMCID: PMC8233649.
Jiménez-Labaig P, Pacheco-Barcia V, Cebrià A, Gálvez F, Obispo B, Páez D, Quílez A, Quintanar T, Ramchandani A, Remon J, Rogado J, Sánchez DA, Sánchez-Cánovas M, Sanz-García E, Sesma A, Tarazona N, Cotés A, González E, Bosch-Barrera J, Fernández A, Felip E, Vera R, Rodríguez-Lescure Á, Élez E. Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM). ESMO Open. 2021 Aug;6(4):100215. doi: 10.1016/j.esmoop.2021.100215. Epub 2021 Jul 26. PMID: 34325108; PMCID: PMC8332651.
Popat S, Brustugun OT, Cadranel J, Felip E, Garassino MC, Griesinger F, Helland Å, Hochmair M, Pérol M, Bent-Ennakhil N, Kruhl C, Novello S. Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. Lung Cancer. 2021 Jul;157:9-16. doi: 10.1016/j.lungcan.2021.05.017. Epub 2021 May 24. PMID: 34051652.
Byers LA, Navarro A, Schaefer E, Johnson M, Özgüroğlu M, Han JY, Bondarenko I, Cicin I, Dragnev KH, Abel A, Wang X, McNeely S, Hynes S, Lin AB, Forster M. A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer. Clin Lung Cancer. 2021 Nov;22(6):531-540. doi: 10.1016/j.cllc.2021.04.005. Epub 2021 Apr 24. PMID: 34034991.
Tan B, Khattak A, Felip E, Kelly K, Rich P, Wang D, Helwig C, Dussault I, Ojalvo LS, Isambert N. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort. Target Oncol. 2021 Jul;16(4):435-446. doi: 10.1007/s11523-021-00809-2. Epub 2021 May 19. PMID: 34009501; PMCID: PMC8266790.
Oleas D, Bolufer M, Agraz I, Felip E, Muñoz E, Gabaldón A, Bury R, Espinel E, Serón D, García-Carro C, Soler MJ. Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience. Clin Kidney J. 2020 Feb 10;14(5):1364-1370. doi: 10.1093/ckj/sfaa008. PMID: 34221369; PMCID: PMC8247740.
Garrido P, Paz-Ares L, Majem M, Morán T, Trigo JM, Bosch-Barrera J, Garcίa-Campelo R, González-Larriba JL, Sánchez-Torres JM, Isla D, Viñolas N, Camps C, Insa A, Juan Ó, Massuti B, Paredes A, Artal Á, López-Brea M, Palacios J, Felip E. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. Cancer Med. 2021 Sep;10(17):5878-5888. doi: 10.1002/cam4.4135. Epub 2021 Jul 23. PMID: 34296539; PMCID: PMC8419773.
Cedres S, Assaf JD, Iranzo P, Callejo A, Pardo N, Navarro A, Martinez-Marti A, Marmolejo D, Rezqallah A, Carbonell C, Frigola J, Amat R, Pedrola A, Dienstmann R, Felip E. Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort. Sci Rep. 2021 Nov 1;11(1):21357. doi: 10.1038/s41598-021-00831-4. PMID: 34725384; PMCID: PMC8560806.
Jiménez-Yuste V, de la Corte-Rodríguez H, Álvarez-Román MT, Martín-Salces M, Querol F, Bonanad S, Mingot-Castellano ME, Fernández-Mosteirín N, Canaro M, Santamaría A, Núñez R, García-Frade LJ, Martinoli C, Kim HK. Ultrasound evaluation of joint damage and disease activity in adult patients with severe haemophilia A using the HEAD-US system. Haemophilia. 2021 May;27(3):479-487. doi: 10.1111/hae.14280. Epub 2021 Feb 23. PMID: 33620134.
Solomon BJ, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Shaw AT. Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer. Future Oncol. 2021 Dec 1;17(34):4649-4656. doi: 10.2217/fon-2021-0904. Epub 2021 Sep 29. PMID: 34585621.
Felip E, Burotto M, Zvirbule Z, Herraez-Baranda LA, Chanu P, Kshirsagar S, Maiya V, Chan P, Pozzi E, Marchand M, Monchalin M, Tanaka K, Tosti N, Wang B, Restuccia E. Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer. Clin Pharmacol Drug Dev. 2021 Oct;10(10):1142-1155. doi: 10.1002/cpdd.936. Epub 2021 Mar 31. PMID: 33788415; PMCID: PMC8518371.
Bueno F, Solano C, Vázquez L, Giménez E, de la Cámara R, Albert E, Rovira M, Espigado I, Martín Calvo C, López-Jiménez J, Suárez-Lledó M, Chinea A, Esquirol A, Pérez A, Bermúdez A, Saldaña R, Heras I, González-Huerta AJ, Torrado T, Batlle M, Jiménez S, Vallejo C, Barba P, Cuesta MÁ, Duarte R, Piñana JL, Navarro D; Spanish Group of Hematopoietic Transplantation, Cell Therapy (GETH). Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group. Transpl Infect Dis. 2021 Aug;23(4):e13627. doi: 10.1111/tid.13627. Epub 2021 May 18. PMID: 33908148.
Bouza E, Martín Jiménez M, Alemany L, Arribas J, Bañares R, Barragán MB, Eiros Bouza JM, Felip E, Fernández-Capetillo O, Gracia D, López-Vélez R, Bautista Mollar J, Muñoz P, Paz-Ares L, Torné A, Tovar J, Valencia E, Palomo E. Overview of virus and cancer relationships. Position paper. Rev Esp Quimioter. 2021 Dec;34(6):525-555. doi: 10.37201/req/058.2021. Epub 2021 Aug 5. PMID: 34348449; PMCID: PMC8638760.
Goss GD, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Isla D, Morabito A, Min YJ, Ardizzoni A, Bender S, Cseh A, Felip E. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial. EClinicalMedicine. 2021 Jun 18;37:100940. doi: 10.1016/j.eclinm.2021.100940. PMID: 34195574; PMCID: PMC8225678.
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csoszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O’Brien M; Rao S; Hotta K; Leiby MA; Lubiniecki GM; Shentu Y; Rangwala R; Brahmer JR; KEYNOTE-024 Investigators. 2016. N Engl J Med. 375: 1823-1833. IF:59,558
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial.Herbst RS; Baas P; Kim DW; Felip E; Pérez-Gracia JL; Han JY; Molina J; Kim JH; Arvis CD; Ahn MJ; Majem M; Fidler MJ; de Castro G; Garrido M; Lubiniecki GM; Shentu Y; Im E; Dolled-Filhart M; Garon EB. 2016. Lancet. 387: 1540-1550. IF:44,002
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): Results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.Quoix E; Lena H; Losonczy G; Forget F; Chouaid C; Papai Z; Gervais R; Ottensmeier C; Szczesna A; Kazarnowicz A; Beck JT; Westeel V; Felip E; Debieuvre D; Madroszyk A; Adam J; Lacoste G; Tavernaro A; Bastien B; Halluard C; Palanché T; Limacher JM. 2016. Lancet Oncol. 17: 212-223. IF:26,509
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.Kim DW; Mehra R; Tan DS; Felip E; Chow LQ; Camidge DR; Vansteenkiste J; Sharma S; De Pas T; Riely GJ; Solomon BJ; Wolf J; Thomas M; Schuler M; Liu G; Santoro A; Sutradhar S; Li S; Szczudlo T; Yovine A; Shaw AT. 2016. Lancet Oncol. 17: 452-463. IF:26,509
Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: Results from PROFILE 1014.Solomon BJ; Cappuzzo F; Felip E; Blackhall FH; Costa DB; Kim DW; Nakagawa K; Wu YL; Mekhail T; Paolini J; Tursi J; Usari T; Wilner KD; Selaru P; Mok TS. 2016. J Clin Oncol. 34: 2858-2865. IF:20,982
Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: Results from ASCEND-2.Crinò L; Ahn MJ; De Marinis F; Groen HJ; Wakelee H; Hida T; Mok T; Spigel D; Felip E; Nishio M; Scagliotti G; Branle F; Emeremni C; Quadrigli M; Zhang J; Shaw AT. 2016. J Clin Oncol. 34: 2866-2873. IF:20,982
Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer.Reck, Martin; Luft, Alexander; Szczesna, Aleksandra; Havel, Libor; Kim, Sang-We; Akerley, Wallace; Pietanza, Maria Catherine; Wu, Yi-long; Zielinski, Christoph; Thomas, Michael; Felip, Enriqueta; Gold, Kathryn; Horn, Leora; Aerts, Joachim; Nakagawa, Kazuhiko; Lorigan, Paul; Pieters, Anne; Sanchez, Teresa Kong; Fairchild, Justin; Spigel, David. 2016. J Clin Oncol. 34: 3740-3748. IF:20,982
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: Phase III randomized LUX-Lung 5 trial.Schuler M; Yang JC; Park K; Kim JH; Bennouna J; Chen YM; Chouaid C; De Marinis F; Feng JF; Grossi F; Kim DW; Liu X; Lu S; Strausz J; Vinnyk Y; Wiewrodt R; Zhou C; Wang B; Chand VK; Planchard D; LUX-Lung 5 Investigators. 2016. Ann Oncol. 27: 417-423.IF:9,269
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.Chatterjee M; Turner DC; Felip E; Lena H; Cappuzzo F; Horn L; Garon EB; Hui R; Arkenau HT; Gubens MA; Hellmann MD; Dong D; Li C; Mayawala K; Freshwater T; Ahamadi M; Stone J; Lubiniecki GM; Zhang J; Im E; De Alwis DP; Kondic AG; Fløtten Ø. 2016. Ann Oncol. 27: 1291-1298. IF:9,269
141PD: Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND-1 and ASCEND-2 trials..Felip E; Crinò L; Kim DW; Spigel DR; Nishio M; Mok T; Scagliotti G; Cesic D; Sutradhar S; Shaw AT. 2016. J Thorac Oncol. IF:5,040
178P: Continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival (PPS) in ALK+ NSCLC..Tan D; Liu G; Kim DW; Thomas M; Felip E; Signorovitch J; Zhang J; Szczudlo T; Shaw AT. 2016. J Thorac Oncol. IF:5,040
193TiP: CheckMate 171: A multicenter phase 2 trial of nivolumab (nivo) in patients (pts) with stage IIIB/IV squamous cell (SQ) NSCLC who have received =1 prior systemic treatment..Felip E; Van Meerbeeck J; Wolf J; Ardizzoni A; Li A; Srinivasan S; Popat S. 2016. J Thorac Oncol. IF:5,040
Economic analysis of first-line treatment with erlotinib in an EGFR-mutated population with advanced NSCLC.Vergnenegre A; Massuti B; de Marinis F; Carcereny E; Felip E; Do P; Sanchez JM; Arez LP; Chouaid C; Rosell R; GECP; AIOT and GFPC groups. 2016. J Thorac Oncol. 11: 801-807. IF:5,040
MINI01.01: Whole Body and Intracranial Efficacy of Ceritinib in ALK-inhibitor Naïve Patients with ALK+ NSCLC and Brain Metastases: Results of ASCEND 1 and 3: Topic: Medical Oncology..Shaw AT; Spigel DR; Tan DS; Kim DW; Mehra R; Orlov S; Park K; Yu CJ; Mok T; Nishio M; Scagliotti G; Sutradhar S; Cesic D; Felip E. 2016. J Thorac Oncol. IF:5,040
ORAL01.04: Phase II Trial of Atezolizumab for Patients with PD-L1-Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results: Topic: Medical Oncology..Wakelee H; Patel JD; Heist R; Balmanoukian A; Besse B; Felip E; Carcereny Costa E; Chow LQ; Koczywas M; Garassino MC; Christoph D; Toh CK; Johnson ML; Chaft J; Kurata T; Qiu J; Kowanetz M; Coleman S; Mocci S; Sandler A; Gettinger SN; Peters S. 2016. J Thorac Oncol. IF:5,040
ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016..Dittrich C; Kosty M; Jezdic S; Pyle D; Berardi R; Bergh J; El Saghir N; Lotz JP; Österlund P; Pavlidis N; Purkalne G; ESMO/ASCO Global Curriculum Working Group. 2016. Ann Oncol. 27: 1378-1381. IF:9,269
P2.41 (also presented as PD1.06): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment: Track: Immunotherapy..Herbst RS; Baas P; Perez-Gracia JL; Felip E; Kim DW; Han JY; Molina J; Kim JH; Arvis CD; Ahn MJ; Majem M; Fidler MJ; Surmont V; De Castro G; Garrido M; Shentu Y; Dolled-Filhart M; Im E; Garon EB. 2016. J Thorac Oncol. IF:5,040
P2.39: Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab: Track: Immunotherapy..Ramalingam S; Hui R; Gandhi L; Carcereny E; Felip E; Ahn MJ; Eder JP; Balmanoukian AS; Leighl N; Aggarwal C; Horn L; Patnaik A; Middleton GW; Gubens M; Hellmann M; Soria JC; Lubiniecki GM; Zhang J; Piperdi B; Garon EB. 2016. J Thorac Oncol. IF:5,040
P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis: Track: Immunotherapy..Borghaei H; Brahmer J; Horn L; Ready N; Steins M; Felip E; Paz-Ares L; Xx X; Barlesi F; Antonia S; Fayette J; Rizvi N; Crino L; Reck M; Erich Eberhardt WE; Hellmann M; Desai K; Li A; Healey D; Spigel D; Mathias C. 2016. J Thorac Oncol. IF:5,040
PD1.06 (also presented as P2.41): Pembrolizumab vs Docetaxel for Previously Treated NSCLC (KEYNOTE-010): Archival vs New Tumor Samples for PD-L1 Assessment..Herbst RS; Baas P; Perez-Gracia JL; Felip E; Kim DW; Han JY; Molina J; Kim JH; Arvis CD; Ahn MJ; Majem M; Fidler MJ; Surmont V; De Castro G; Garrido M; Shentu Y; Dolled-Filhart M; Im E; Garon EB. 2016. J Thorac Oncol. IF:5,040
PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study: Topic: Medical Oncology..Gordon MS; Herbst RS; Horn L; Soria JC; Gandhi L; Felip E; Sequist L; Spigel DR; Antonia SJ; Balmanoukian A; Cassier P; Liu B; Kowanetz M; O’Hear C; Fassò M; Sandler A; Gettinger SN. 2016. J Thorac Oncol. IF:5,040
PS01.55: IMpower010: Phase III Study of Atezolizumab vs BSC After Adjuvant Chemotherapy in Patients with Completely Resected NSCLC: Topic: Medical Oncology..Vallieres E; Felip E; Altorki N; Zhou C; Zuo Y; Howland M; Xia F; Hoang T; Sandler A; Wakelee H. 2016. J Thorac Oncol. IF:5,040
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma..Rice D; Chansky K; Nowak A; Pass H; Kindler H; Shemanski L; Opitz I; Call S; Hasegawa S; Kernstine K; Atinkaya C; Rea F; Nafteux P; Rusch VW; Mesothelioma Domain of the IASLC Staging and Prognostic Factors Committee, advis. 2016. J Thorac Oncol. 11: 2100-2111. IF:5,040
The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation. Pass H; Giroux D; Kennedy C; Ruffini E; Cangir AK; Rice D; Asamura H; Waller D; Edwards J; Weder W; Hoffmann H; van Meerbeeck JP; Nowak A; Rusch VW; IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participatin. 2016. J Thorac Oncol. 11: 2082-2088. IF:5,040
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.Nowak AK; Chansky K; Rice DC; Pass HI; Kindler HL; Shemanski L; Billé A; Rintoul RC; Batirel HF; Thomas CF; Friedberg J; Cedres S; de Perrot M; Rusch VW; Staging and Prognostic Factors Committee, Advisory Boards and Participating Inst. 2016. J Thorac Oncol. 11: 2089-2099. IF:5,040
The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma..Rusch VW; Chansky K; Kindler HL; Nowak AK; Pass HI; Rice DC; Shemanski L; Galateau-Sallé F; McCaughan BC; Nakano T; Ruffini E; van Meerbeeck JP; Yoshimura M; IASLC Staging and Prognostic Factors Committee, advisory boards, and participati. 2016. J Thorac Oncol. 11: 2112-2119. IF:5,040
Analysis of expression of PTEN/PI3 K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).Cedrés S; Ponce-Aix S; Pardo-Aranda N; Navarro-Mendivil A; Martinez-Marti A; Zugazagoitia J; Sansano I; Montoro MA; Enguita A; Felip E. 2016. Lung Cancer. 96: 1-6. IF:3,767
A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS).Smit EF; Wu YL; Gervais R; Zhou C; Felip E; Feng J; Guclu SZ; Hoiczyk M; Dorokhova E; Freudensprung U; Grange S; Perez-Moreno PD; Mitchell L; Reck M. 2016. Lung Cancer. 99: 94-101. IF:3,767
Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology.Gridelli C; Ascierto PA; Barberis MC; Felip E; Garon EB; O’brien M; Senan S; Casaluce F; Sgambato A; Papadimitrakopoulou V; De Marinis F. 2016. Expert Opin Biol Ther. 16: 1479-1489. IF:3,438
The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results from an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.Gridelli C; Besse B; Brahmer JR; Crinò L; Felip E; de Marinis F. 2016. CLIN LUNG CANCER. 17: 161-168. IF:3,030
Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: Implications for formulation, dose, and dosing frequency in pivotal clinical studies.Planchard D; Brown KH; Kim DW; Kim SW; Ohe Y; Felip E; Leese P; Cantarini M; Vishwanathan K; Jänne PA; Ranson M; Dickinson PA. 2016. Cancer Chemother Pharmacol. 77: 767-776. IF:2,824
Lung cancer in women with a family history of cancer: The Spanish female-specific database WORLD07.Isla D; Felip E; Viñolas N; Provencio M; Majem M; Artal A; Bover I; Lianes P; DE Las Peñas R; Catot S; DE Castro J; Blasco A; Terrasa J; Gonzalez-Larriba JL; Juan O; Dómine M; Bernabe R; Garrido P. 2016. Anticancer Res. 36: 6647-6653. IF:1,895
Thoracic oncology HERMES: European curriculum recommendations for training in thoracic oncology.Gamarra, F.; Noël, J.-L.; Brunelli, A.; Dingemans, A.-M.C.; Felip, E.; Gaga, M.; Grigoriu, B.D.; Hardavella, G.; Huber, R.M.; Janes, S.; Massard, G.; Putora, P.M.; Sculier, J.-P.; Schnabel, P.A.; Ramella, S.; Van Raemdonck, D.; Meert, A.-P.. 2016. Breathe. 12: 249-255.
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016..Dittrich C; Kosty M; Jezdic S; Pyle D; Berardi R; Bergh J; El-Saghir N; Lotz JP; Österlund P; Pavlidis N; Purkalne G; Awada A; Banerjee S; Bhatia S; Bogaerts J; Buckner J; Cardoso F; Casali P; Chu E; Close JL; Coiffier B; Connolly R; Coupland S; De Petris L; De Santis M; de Vries EG; Dizon DS; Duff J; Duska LR; Eniu A; Ernstoff M; Felip E; Fey MF; Gilbert J; Girard N; Glaudemans AW; Gopalan PK; Grothey A; Hahn SM; Hanna D; Herold C; Herrstedt J; Homicsko K; Jones DV; Jost L; Keilholz U; Khan S; Kiss A; Köhne CH; Kunstfeld R; Lenz HJ; Lichtman S; Licitra L; Lion T; Litière S; Liu L; Loehrer PJ; Markham MJ; Markman B; Mayerhoefer M; Meran JG; Michielin O; Moser EC; Mountzios G; Moynihan T; Nielsen T; Ohe Y; Öberg K; Palumbo A; Peccatori FA; Pfeilstöcker M; Raut C; Remick SC; Robson M; Rutkowski P; Salgado R; Schapira L; Schernhammer E; Schlumberger M; Schmoll HJ; Schnipper L; Sessa C; Shapiro CL; Steele J; Sternberg CN; Stiefel F; Strasser F; Stupp R; Sullivan R; Tabernero J; Travado L; Verheij M; Voest E; Vokes E; Von Roenn J; Weber JS; Wildiers H; Yarden Y. 2016. ESMO Open.
Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016 Apr; 387(10027): 1540-50
Eberhardt WE, De Ruysscher D, Weder W, Le Péchoux C, De Leyn P, Hoffmann H, Westeel V, Stahel R, Felip E, Peters S. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann. Oncol. 2015 Aug; 26(8): 1573-88
Heigener DF, Pereira JR, Felip E, Mazal J, Manzyuk L, Tan EH, Merimsky O, Sarholz B, Esser R, Gatzemeier U. Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial. Target Oncol 2015 Jun; 10(2): 255-65
Felip E, Concha A, de Castro J, Gómez-Román J, Garrido P, Ramírez J, Isla D, Sanz J, Paz-Ares L, López-Ríos F. Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol 2015 Feb; 17(2): 103-12
Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, Ercan D, Matthews SE, Cantarini M, Barrett JC, Janne PA, Oxnard GR. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.Nat. Med. 2015 Jun; 21(6): 560-2
De Mattos-Arruda L, Mayor R, Ng CK, Weigelt B, Martínez-Ricarte F, Torrejón D, Oliveira M, Arias A, Raventós C, Tang J, Guerini-Rocco E, Martínez-Sáez E, Lois S, Marín O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramón y Cajal S, Carles J, Rodón J, González-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 2015; 6: 8839
Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Pálmer HG, Dawood S, Rodón J, Cajal SR, Campo JM, Felip E, Tabernero J, Cortes J. ERRATUM: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity. Sci Rep 2015; 5: 8179
Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 2015 Apr; 372(18): 1689-99
Karachaliou N, Codony-Servat J, Teixidó C, Pilotto S, Drozdowskyj A, Codony-Servat C, Giménez-Capitán A, Molina-Vila MA, Bertran-Alamillo J, Gervais R, Massuti B, Morán T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S, González-Cao M, Morales-Espinosa D, Verlicchi A, Crisetti E, Chaib I, Santarpia M, Luis Ramírez J, Bosch-Barrera J, Felipe Cardona A, de Marinis F, Lopez-Vivanco G, Miguel Sánchez J, Vergnenegre A, Sánchez Hernández JJ, Sperduti I, Bria E, Rosell R. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. Sci Rep 2015; 5: 17499
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2015 Oct; 373(17): 1627-39
Karachaliou N, Mayo-de las Casas C, Queralt C, de Aguirre I, Melloni B, Cardenal F, García-Gómez R, Massuti B, Sanchez JM, Porta R, Ponce-Aix S, Morán T, Carcereny E, Felip E, Bover I, Insa A, Reguart N, Isla D, Vergnenegre A, de Marinis F, Gervais R, Corre R, Paz-Ares L, Morales-Espinosa D, Viteri S, Drozdowskyj A, Jordana-Ariza N, Ramirez-Serrano JL, Molina-Vila MA, Rosell R. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. JAMA Oncol 2015 May; 1(2): 149-57
Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Isla D, Guclu SZ, Morabito A, Min YJ, Ardizzoni A, Gadgeel SM, Wang B, Chand VK, Goss GD. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2015 Aug; 16(8): 897-907
Vansteenkiste JF, Canon JL, Braud FD, Grossi F, De Pas T, Gray JE, Su WC, Felip E, Yoshioka H, Gridelli C, Dy GK, Thongprasert S, Reck M, Aimone P, Vidam GA, Roussou P, Wang YA, Di Tomaso E, Soria JC. Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study. J Thorac Oncol 2015 Sep; 10(9): 1319-27
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 2015 May; 372(21): 2018-28
Cedrés S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, Martinez-Marti A, Martínez P, Felip E. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS ONE 2015; 10(3): e0121071
Cappuzzo F, Moro-Sibilot D, Gautschi O, Boleti E, Felip E, Groen HJ, Germonpré P, Meldgaard P, Arriola E, Steele N, Fox J, Schnell P, Engelsberg A, Wolf J. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus. Lung Cancer 2015 Feb; 87(2): 89-95
Dienstmann R, Rodón J, Prat A, Pérez-García J, Adamo B, Felip E, Cortes J, Iafrate AJ, Nuciforo P, Tabernero J. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann. Oncol. 2014 Mar; 25(3): 552-63
Remon J, Molina-Montes E, Majem M, Lianes P, Isla D, Garrido P, Felip E, Viñolas N, de Castro J, Artal A, Sánchez MJ. Lung cancer in women: an overview with special focus on Spanish women. Clin Transl Oncol 2014 Jun; 16(6): 517-28
Martínez P, Martinez-Marti A, Navarro A, Cedrés S, Felip E. Molecular targeted therapy for early-stage non-small-cell lung cancer: will it increase the cure rate? Lung Cancer 2014 May; 84(2): 97-100
Janne PA, Cohen RB, Laird AD, Macé S, Engelman JA, Ruiz-Soto R, Rockich K, Xu J, Shapiro GI, Martínez P, Felip E. Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors. J Thorac Oncol 2014 Mar; 9(3): 316-23
Costa C, Molina MA, Drozdowskyj A, Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervais R, Massuti B, Wei J, Morán T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S, Taron M, Ono M, Giannikopoulos P, Bivona T, Rosell R. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin. Cancer Res. 2014 Apr; 20(7): 2001-10
Besse B, Adjei A, Baas P, Meldgaard P, Nicolson M, Paz-Ares L, Reck M, Smit EF, Syrigos K, Stahel R, Felip E, Peters S. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann. Oncol. 2014 Aug; 25(8): 1475-84
Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med. 2014 Mar; 370(13): 1189-97
Peghin M, Ruiz-Camps I, Garcia-Vidal C, Cervera C, Andreu J, Martín M, Gavaldá J, Gudiol C, Moreno A, Felip E, Pahissa A. Unusual forms of subacute invasive pulmonary aspergillosis in patients with solid tumors. J. Infect. 2014 Oct; 69(4): 387-95
Martínez P, Sales Fidalgo PA, Felip E. Ganitumab for the treatment of small-cell lung cancer. Expert Opin Investig Drugs 2014 Oct; 23(10): 1423-32
Morán T, Felip E, Keedy V, Borghaei H, Shepherd FA, Insa A, Brown H, Fitzgerald T, Sathyanarayanan S, Reilly JF, Mauro D, Hsu K, Yan L, Johnson DH. Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial. Exp Hematol Oncol 2014; 3(1): 26
Peters S, Weder W, Dafni U, Kerr KM, Bubendorf L, Meldgaard P, O’Byrne KJ, Wrona A, Vansteenkiste J, Felip E, Marchetti A, Savic S, Lu S, Smit E, Dingemans AM, Blackhall FH, Baas P, Camps C, Rosell R, Stahel RA. Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters. J Thorac Oncol 2014 Nov; 9(11): 1675-84
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 2014 Dec; 371(23): 2167-77
Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Pálmer HG, Dawood S, Rodón J, Cajal SR, Ramón y Cajal S, del Campo JM, Ramony Cajal S, Felip E, Tabernero J, Cortes J. Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. Sci Rep 2013; 3: 3544
Vansteenkiste J, De Ruysscher D, Eberhardt WE, Lim E, Senan S, Felip E, Peters S. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2013 Oct; 24 Suppl 6: vi89-98
Serra V, Vivancos A, Puente XS, Felip E, Silberschmidt D, Caratù G, Parra JL, De Mattos-Arruda L, Grueso J, Hernandez-Losa J, Arribas J, Prudkin L, Nuciforo P, Scaltriti M, Seoane J, Baselga J. Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation. Cancer Discov 2013 Nov; 3(11): 1238-44
Scagliotti GV, Felip E, Besse B, von Pawel J, Mellemgaard A, Reck M, Bosquee L, Chouaid C, Lianes-Barragán P, Paul EM, Ruiz-Soto R, Sigal E, Ottesen LH, Lechevalier T. An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer. J Thorac Oncol 2013 Dec; 8(12): 1529-37
Cedrés S, Montero MA, Zamora E, Martínez A, Martínez P, Fariñas L, Navarro A, Torrejón D, Gabaldon A, Ramón y Cajal S, Felip E. Expression of Wilms’ tumor gene (WT1) is associated with survival in malignant pleural mesothelioma. Clin Transl Oncol 2013 Dec;
Gamarra F, Boffetta P, De Ruysscher D, Felip E, Gaga M, Grigoriu B, Huber RM, Janes SM, Marquette CH, Massard G, Noel JL, Sculier JP, Meert AP. Thoracic Oncology HERMES syllabus: setting the basis for thoracic oncology training in Europe. Eur. Respir. J. 2013 Sep; 42(3): 568-71
Stahel R, Peters S, Baas P, Brambilla E, Cappuzzo F, De Ruysscher D, Eberhardt WE, Felip E, Fennell D, Marchetti A, Paz-Ares L, Adjei AA. Strategies for improving outcomes in NSCLC: a look to the future.Lung Cancer 2013 Dec; 82(3): 375-82
Camps C, Felip E, Garcia-Campelo R, Trigo JM, Garrido P. SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013. Clin Transl Oncol 2013 Dec; 15(12): 977-84
Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2013 Oct; 24 Suppl 6: vi99-105
Reeder-Hayes K, Felip E, Patt D, Jaffee E. Women in oncology: progress, challenges, and keys to success.Am Soc Clin Oncol Educ Book 2013; : 448-55
Mazieres J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, Moro-Sibilot D, Dansin E, Chouaid C, Wislez M, Diebold J, Felip E, Rouquette I, Milia JD, Gautschi O. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J. Clin. Oncol. 2013 Jun; 31(16): 1997-2003
Cedrés S, Fariñas L, Stejpanovic N, Martínez P, Martínez A, Zamora E, Montero MA, Felip E. Bone metastases with nerve root compression as a late complication in patient with epithelial pleural mesothelioma. J Thorac Dis 2013 Apr; 5(2): E35-7
Martínez P, Hernandez-Losa J, Montero MA, Cedrés S, Castellví J, Martinez-Marti A, Tallada N, Murtra-Garrell N, Navarro-Mendivill A, Rodríguez-Freixinos V, Canela M, Ramón y Cajal S, Felip E. Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. PLoS ONE 2013; 8(1): e52261
Felip E, Martinez-Marti A, Martínez P, Cedrés S, Navarro A. Adjuvant treatment of resected nonsmall cell lung cancer: state of the art and new potential developments. Curr Opin Oncol 2013 Mar; 25(2): 115-20
Soria JC, Baselga J, Hannah A, Felip E, Calvo E, Armand JP, Harbison CT, Park JG, Zhang J, Pathak H, Herbst RS. Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. Eur J Cancer 2013 May; 49(8): 1815-24
Chan AT, Grégoire V, Lefebvre JL, Licitra L, Hui EP, Leung SF, Felip E. Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2012 Oct; 23 Suppl 7: vii83-5
Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2012 Oct; 23 Suppl 7: vii56-64
Felip E, Martínez P. Can sensitivity to cytotoxic chemotherapy be predicted by biomarkers? Ann. Oncol. 2012 Sep; 23 Suppl 10: x189-92
Cedrés S, Torrejón D, Martínez A, Martínez P, Navarro A, Zamora E, Mulet-Margalef N, Felip E. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol 2012 Nov; 14(11): 864-9
Felip E, Martinez-Marti A. DNA repair protein expression in resected NSCLC: a different predictive value for platinum benefit in adenocarcinoma versus squamous-cell carcinoma? Ann. Oncol. 2012 Sep; 23(9): 2211-4
Felip E, Ranson M, Cedrés S, Dean E, Brewster M, Martínez P, McNally V, Ross G, Galdermans D. A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancer. Clin Lung Cancer 2012 Nov; 13(6): 432-41
Cedrés S, Mulet-Margalef N, Montero MA, Martínez P, Martínez A, Felip E. Rectal metastases from squamous cell carcinoma: a case report and review of the literature. Case Rep Med 2012; 2012: 947524
Cedrés S, Montero MA, Martínez P, Martínez A, Rodríguez-Freixinos V, Torrejón D, Gabaldon A, Salcedo M, Ramón y Cajal S, Felip E. Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). Lung Cancer 2012 Jul; 77(1): 192-8
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, García-Gómez R, Pallarés C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Morán T, Insa A, de Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jiménez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sánchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar; 13(3): 239-46
Martínez P, Felip E. Brain metastases: the need for a more tailored approach in non-small-cell lung cancer patients. Clin Transl Oncol 2012 Jan; 14(1): 1-2
Dienstmann R, De Dosso S, Felip E, Tabernero J. Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. Mol Oncol 2012 Feb; 6(1): 15-26
Laskin J, Crinò L, Felip E, Franke F, Gorbunova V, Groen H, Jiang GL, Reck M, Schneider CP. Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390). J Thorac Oncol 2012 Jan; 7(1): 203-11
Viñolas N, Provencio M, Reguart N, Cardenal F, Alberola V, Sánchez-Torres JM, Barón FJ, Cobo M, Maestu I, Moreno I, Mesía C, Izquierdo A, Felip E, López-Brea M, Márquez A, Sánchez-Ronco M, Taron M, Santarpia MC, Rosell R. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer 2011 Feb; 71(2): 191-8
Stahel R, Thatcher N, Früh M, Le Péchoux C, Postmus PE, Sorensen JB, Felip E. 1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. Ann. Oncol. 2011 Sep; 22(9): 1973-80
Gridelli C, Stahel R, Besse B, Ciardiello F, Felip E, Gasparini S, Graziano P, Rossi A, de Marinis F. Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting. Lung Cancer 2011 Dec; 74(3): 544-8
Carbone DP, Felip E. Adjuvant therapy in non-small cell lung cancer: future treatment prospects and paradigms. Clin Lung Cancer 2011 Sep; 12(5): 261-71
Dienstmann R, Felip E. Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development. Expert Opin Biol Ther 2011 Sep; 11(9): 1223-31
Cedrés S, Nuñez I, Longo M, Martínez P, Checa E, Torrejón D, Felip E. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer 2011 May; 12(3): 172-9
Felip E, Gridelli C, Baas P, Rosell R, Stahel R. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann. Oncol. 2011 Jul; 22(7): 1507-19
Dienstmann R, Martínez P, Felip E. Personalizing therapy with targeted agents in non-small cell lung cancer. Oncotarget 2011 Mar; 2(3): 165-77
Reck M, Hermes A, Tan EH, Felip E, Klughammer B, Baselga J. Tissue sampling in lung cancer: a review in light of the MERIT experience. Lung Cancer 2011 Oct; 74(1): 1-6
Altorki N, Lane ME, Bauer T, Lee PC, Guarino MJ, Pass H, Felip E, Peylan-Ramu N, Gurpide A, Grannis FW, Mitchell JD, Tachdjian S, Swann RS, Huff A, Roychowdhury DF, Reeves A, Ottesen LH, Yankelevitz DF. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J. Clin. Oncol. 2010 Jul; 28(19): 3131-7
Felip E, Rosell R, Maestre JA, Rodríguez-Paniagua JM, Morán T, Astudillo J, Alonso G, Borro JM, González-Larriba JL, Torres A, Camps C, Guijarro R, Isla D, Aguiló R, Alberola V, Padilla J, Sánchez-Palencia A, Sanchez JJ, Hermosilla E, Massuti B. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J. Clin. Oncol. 2010 Jul; 28(19): 3138-45
Tan EH, Ramlau R, Pluzanska A, Kuo HP, Reck M, Milanowski J, Au JS, Felip E, Yang PC, Damyanov D, Orlov S, Akimov M, Delmar P, Essioux L, Hillenbach C, Klughammer B, McLoughlin P, Baselga J. A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer. Ann. Oncol. 2010 Feb; 21(2): 217-22
Reck M, Frickhofen N, Cedrés S, Gatzemeier U, Heigener D, Fuhr HG, Thall A, Lanzalone S, Stephenson P, Ruiz-Garcia A, Chao R, Felip E. Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study. Lung Cancer 2010 Nov; 70(2): 180-7
Crinò L, Weder W, van Meerbeeck J, Felip E. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010 May; 21 Suppl 5: v103-15
D’Addario G, Früh M, Reck M, Baumann P, Klepetko W, Felip E. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010 May; 21 Suppl 5: v116-9
Stahel RA, Weder W, Lievens Y, Felip E. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010 May; 21 Suppl 5: v126-8
Grégoire V, Lefebvre JL, Licitra L, Felip E. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010 May; 21 Suppl 5: v184-6
Chan AT, Grégoire V, Lefebvre JL, Licitra L, Felip E. Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010 May; 21 Suppl 5: v187-9
Cedrés S, Prat A, Martínez P, Pallisa E, Sala G, Andreu J, del Campo JM, Quispe I, Baselga J, Felip E. Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib. Lung Cancer 2009 Nov; 66(2): 257-61
Muñoz E, Cedrés S, Felip E. Rare tumours of the chest. Eur. J. Cancer 2009 Sep; 45 Suppl 1: 400-1
Felip E, Garrido P, Trigo JM, López-Brea M, Paz-Ares L, Provencio M, Isla D. SEOM guidelines for the management of non-small-cell lung cancer (NSCLC). Clin Transl Oncol 2009 May; 11(5): 284-9
Sørensen M, Felip E. Small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 2009 May; 20 Suppl 4: 71-2
Felip E, Rojo F, Reck M, Heller A, Klughammer B, Sala G, Cedrés S, Peralta S, Maacke H, Foernzler D, Parera M, Möcks J, Saura C, Gatzemeier U, Baselga J. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin. Cancer Res. 2008 Jun; 14(12): 3867-74
Chan AT, Felip E. Nasopharyngeal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 2008 May; 19 Suppl 2: ii81-2
Pivot X, Felip E. Squamous cell carcinoma of the head and neck: ESMO clinical Recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 2008 May; 19 Suppl 2: ii79-80
Stahel RA, Weder W, Felip E. Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 2008 May; 19 Suppl 2: ii43-4
D’Addario G, Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 2008 May; 19 Suppl 2: ii39-40
Briasoulis E, Pavlidis N, Felip E. Cancers of unknown primary site: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann. Oncol. 2008 May; 19 Suppl 2: ii106-7
Felip E. Small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.Ann. Oncol. 2007 Apr; 18 Suppl 2: ii32-3